AHB
REGN icon

Abner Herrman & Brock’s Regeneron Pharmaceuticals REGN Stock Holding History

Abner Herrman & Brock’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Hold
557
– – 0.03% 84
2026
Q1 		$430K Hold
557
– – 0.05% 73
2025
Q4 		$430K Hold
557
– – 0.04% 76
2025
Q3 		$313K Buy
+557
New +$315K 0.03% 92

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Abner Herrman & Brock's REGN Position: Q2 2026 in Review

Abner Herrman & Brock held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 557 shares worth $347K. The position accounts for 0.03% of the portfolio, ranked #84.

Abner Herrman & Brock first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $430K in Q1 2026. 180 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Abner Herrman & Brock held 557 shares of Regeneron Pharmaceuticals worth $347K as of Q2 2026.
  • Abner Herrman & Brock left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Abner Herrman & Brock's portfolio in Q2 2026, its #84 holding.
  • Abner Herrman & Brock first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Abner Herrman & Brock's Regeneron Pharmaceuticals position peaked at $430K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Abner Herrman & Brock's 13F filing for Q2 2026, filed 8 Jul 2026.